Pricing Log in Create free account
Friday 6 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

160.47 5.58 −3.36%
Market cap
$16.2B
P/E
23.0×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a EV/EBITDA of 16.5×. Over the past ten years it has ranged from 0.0× (June 2019) to 279× (September 2019); the current reading is higher than 35% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 20.7× (10.21%)
FY2024 23.1× (52.73%)
FY2023 48.8× 19.13%
FY2022 41.0× (29.84%)
FY2021 58.4× 27.72%
FY2020 45.7× (52.60%)
FY2019 96.5× (12.25%)
FY2018 110× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 14.6× (29.44%)
Jun 2026 20.6× 33.37%
Mar 2026 15.5× (25.27%)
Dec 2025 20.7× (16.01%)
36 more quarters

Against its own ten years

Low 0.0× High 279×
Ten-year median 25.6×
Current reading's percentile 35

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. compare 10.7×
HLN Haleon PLC Sponsored ADR compare 12.2×
VTRS Viatris Inc. compare 12.3×
UTHR United Therapeutics Corporation compare 14.7×
NBIX Neurocrine Biosciences, Inc. 16.5×
ELAN Elanco Animal Health Incorporated compare 19.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc compare 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on NBIX